Top

Published in:

01-03-2019 | Original Scientific Report (including Papers Presented at Surgical Conferences)

Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1)

Authors: Caroline L. Lopez, Barbara Joos, Detlef K. Bartsch, Jerena Manoharan, Max Albers, Emily P. Slater, Carmen Bollmann, Sylvia Roth, Aninja Bayer, Volker Fendrich

Published in: World Journal of Surgery | Issue 3/2019

Abstract

Objective

Long-acting synthetic somatostatin analogues (SSA) are an essential part of the treatment of neuroendocrine neoplasms. We evaluated the chemopreventive effects of a long-acting somatostatin analogue on the development of pancreatic neuroendocrine neoplasms (pNENs) in a genetically engineered MEN1 knockout mouse model.

Materials and methods

Heterozygote MEN1 knockout mice were injected every 28 days subcutaneously with the somatostatin analogue lanreotide (Somatuline Autogel©; Ipsen Pharma) or a placebo starting at day 35 after birth. Mice were euthanized after 6, 9, 12, 15 and 18 months, and the size and number of pNENs were measured due histological analysis and compared to the placebo group.

Results

The median tumor size of pNENs was statistically significantly smaller after 9 (control group vs. SSA group; 706.476 µm² vs. 195.271 µm²; p = 0.0012), 12 (placebo group vs. SSA group 822.022 vs. 255.482; p ≤ 0.001), 15 (placebo group vs. SSA group 1192.568 vs. 273.533; p ≤ 0.001) and after 18 months (placebo group vs. SSA group 1328.299 vs. 864.587; p ≤ 0.001) in the SSA group. Comparing the amount of tumors in both groups, a significant reduction was achieved in treated Men1^(+/−) mice (41%, p = 0.002). Immunostaining showed, however, no significant difference in the expression of the apoptosis marker caspase-3, but a significant difference in Ki67 index as a marker for tumor cell proliferation (p ≤ 0.005).

Conclusion

Long-acting somatostatin analogues may be an effective chemopreventive approach to delay the progression of MEN1-associated pNENs. After our preclinical results, we would recommend to evaluate the effects of long-acting SSA in a prospective clinical trial.

Brandi ML (2000) Multiple endocrine neoplasia type 1. Rev Endocr Metab Disord 1:275–282CrossRefPubMed

Trump D, Farren B, Wooding C et al (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM Mon J Assoc Phys 89:653–669

Marx S, Spiegel AM, Skarulis MC et al (1998) Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 129:484–494CrossRefPubMed

Carney JA (2005) Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol 29:254–274 (review) CrossRefPubMed

Chandrasekharappa SC, Guru SC, Manickam P et al (1997) Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 276:404CrossRefPubMed

Thomas-Marquez L, Murat A, Delemer B et al (2006) Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 101:266–273CrossRef

Schussheim DH, Skarulis MC, Agarwal SK et al (2001) Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 12:173–178CrossRefPubMed

Carty SE, Helm AK, Amico JA et al (1998) The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 124:1106–1111CrossRefPubMed

Triponez F, Dosseh D, Goudet P et al (2006) Epidemiology data on 108 MEN1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 243(2):265–272CrossRefPubMedPubMedCentral

10.

Goudet P, Murat A, Binquet C et al (2010) Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34:249–255. https://doi.org/10.1007/s00268-009-0290-1 CrossRefPubMed

11.

Thakker RV, Newey PJ, Walls GV et al (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97(9):2990–3011CrossRefPubMed

12.

Falconi M, Bartsch DK, Eriksson B et al (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 95(2):120–134CrossRef

13.

Kulke MH, Anthony LB, Bushnell DL et al (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas; North American Neuroendocrine Tumor Society (NANETS). Pancreas 39(6):735–752CrossRefPubMedPubMedCentral

14.

Dʼsouza SL, Elmunzer BJ, Scheiman JM (2014) Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome. J Clin Gastroenterol 48(5):458–461CrossRef

15.

Chu X, Gao X, Jansson L et al (2013) Multiple microvascular alterations in pancreatic islets and neuroendocrine tumors of a Men1 mouse model. Am J Pathol 182(6):2355–2367CrossRefPubMed

16.

Bertolino P, Tong WM, Galendo D et al (2003) Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol 17(9):1880–1892CrossRefPubMed

17.

Harding B, Lemos MC, Reed AAC et al (2009) Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia. Endocr Relat Cancer 16(4):1313–1327CrossRefPubMedPubMedCentral

18.

Papotti M, Bongiovanni M, Volante M et al (2002) Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors—a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461–475CrossRefPubMed

19.

Bousquet C, Puente E, Buscail L et al (2001) Antiproliferative effect of somatostatin and analogs. Chemotherapy 47(suppl2):30–39CrossRefPubMed

20.

Walls GV, Stevenson M, Soukup BS et al (2016) Pasireotide therapy of multiple endocrine neoplasia type 1-associated neuroendocrine tumors in female mice deleted for an Men1 allele improves survival and reduces tumor progression. Endocrinology 157(5):1789–1798. https://doi.org/10.1210/en.2015-1965 CrossRefPubMedPubMedCentral

21.

Cives M, Kunz PL, Morse B et al (2015) Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer 22(1):1–9. https://doi.org/10.1530/ERC-14-0360 Epub 2014 Nov 6 CrossRefPubMed

22.

Fendrich V, Esni F, Garay MV et al (2008) Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology 135(2):621–631CrossRefPubMedPubMedCentral

23.

Cives M, Strosberg J (2015) The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Drugs 75(8):847–858CrossRefPubMed

24.

Grozinsky-Glasberg S, Shimon I, Korbonits M et al (2008) Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 15(3):701–720CrossRefPubMed

25.

Pokuri VK, Fong MK, Iyer R (2016) Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep 918:7CrossRef

26.

Rinke A, Wittenberg M, Schade-Brittinger C et al (2016) PROMID study group. Neuroendocrinology 104:26–32CrossRefPubMed

27.

Caplin ME, Pavel M, Ćwikła JB et al (2016) CLARINET investigators. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer 23(3):191–199. https://doi.org/10.1530/erc-15-0490 CrossRefPubMedPubMedCentral

28.

Quinn TJ, Yuan Z, Adem A et al (2012) Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery 152(6):1068–1077CrossRefPubMedPubMedCentral

29.

Lopez CL, Albers MB, Bollmann C et al (2016) Minimally invasive versus open pancreatic surgery in patients with multiple endocrine neoplasia type 1. World J Surg. https://doi.org/10.1007/s00268-016-3456-7 CrossRefPubMed

Title: Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1)
Authors: Caroline L. Lopez
Barbara Joos
Detlef K. Bartsch
Jerena Manoharan
Max Albers
Emily P. Slater
Carmen Bollmann
Sylvia Roth
Aninja Bayer
Volker Fendrich
Publication date: 01-03-2019
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 3/2019
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-018-4839-8

At a glance: The STEP trials

Springer Medicine

Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1)

Abstract

Objective

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Honorary Authorships in Surgical Literature

Complications After Ostomy Surgery: Emergencies and Obese Patients are at Risk—Data from the Berlin OStomy Study (BOSS)

Perioperative Outcomes of Laparoscopic Repeat Liver Resection for Recurrent HCC: Comparison with Open Repeat Liver Resection for Recurrent HCC and Laparoscopic Resection for Primary HCC

Procedure-Specific Volume and Nurse-to-Patient Ratio: Implications for Failure to Rescue Patients Following Liver Surgery

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments

The Short-Form Inguinal Pain Questionnaire (sf-IPQ): An Instrument for Rating Groin Pain After Inguinal Hernia Surgery in Daily Clinical Practice